<?xml version='1.0' encoding='utf-8'?>
<document id="30479741"><sentence text="Significant drug-drug interaction between warfarin and nafcillin."><entity charOffset="55-64" id="DDI-PubMed.30479741.s1.e0" text="nafcillin" /></sentence><sentence text="Nafcillin, a beta-lactam semisynthetic penicillin, is highly resistant to penicillinase and is similar to other penicillins except that it is primarily metabolized in the liver"><entity charOffset="0-9" id="DDI-PubMed.30479741.s2.e0" text="Nafcillin" /><entity charOffset="13-24" id="DDI-PubMed.30479741.s2.e1" text="beta-lactam" /><entity charOffset="39-49" id="DDI-PubMed.30479741.s2.e2" text="penicillin" /><entity charOffset="112-123" id="DDI-PubMed.30479741.s2.e3" text="penicillins" /><pair ddi="false" e1="DDI-PubMed.30479741.s2.e0" e2="DDI-PubMed.30479741.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30479741.s2.e0" e2="DDI-PubMed.30479741.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30479741.s2.e0" e2="DDI-PubMed.30479741.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30479741.s2.e0" e2="DDI-PubMed.30479741.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30479741.s2.e1" e2="DDI-PubMed.30479741.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30479741.s2.e1" e2="DDI-PubMed.30479741.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30479741.s2.e1" e2="DDI-PubMed.30479741.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30479741.s2.e2" e2="DDI-PubMed.30479741.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30479741.s2.e2" e2="DDI-PubMed.30479741.s2.e3" /></sentence><sentence text=" It is believed that nafcillin causes CYP3A4 enzyme induction which decreases warfarin's half-life"><entity charOffset="21-30" id="DDI-PubMed.30479741.s3.e0" text="nafcillin" /></sentence><sentence text=" The onset of CYP3A4 induction by nafcillin occurs within the first 7 days, but maximal effects may take up to 2 weeks" /><sentence text=" Once nafcillin is discontinued, the effects persist for several weeks"><entity charOffset="6-15" id="DDI-PubMed.30479741.s5.e0" text="nafcillin" /></sentence><sentence text=" A 79-year-old male with a history of atrial fibrillation and a 53-year-old male with a history of recurrent venous thromboembolism required significantly higher weekly warfarin doses during courses of nafcillin therapy"><entity charOffset="202-211" id="DDI-PubMed.30479741.s6.e0" text="nafcillin" /></sentence><sentence text=" Both patients required a 2" /><sentence text="5-3" /><sentence text="5-fold increase from their baseline weekly warfarin dose to achieve therapeutic international normalized ratios (INRs) while on nafcillin"><entity charOffset="128-137" id="DDI-PubMed.30479741.s9.e0" text="nafcillin" /></sentence><sentence text=" Traditional protocol-driven warfarin management can result in suboptimal anticoagulation in patients on warfarin and nafcillin"><entity charOffset="118-127" id="DDI-PubMed.30479741.s10.e0" text="nafcillin" /></sentence><sentence text="" /></document>